Concepedia

David L. Ramírez

DL

Statistics

Publications

5

Citations

125

H-Index

5

Active since

2016

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

David L. Ramírez is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, breast cancer, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2016–2025

5

Publications

5

A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity

Jennifer K. Litton, Marion E. Scoggins, David L. Ramírez et al. · npj Breast Cancer · 2017 · 56 citations · Full text

A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer

Clinton Yam, Gaiane M. Rauch, Tanbin Rahman et al. · Investigational New Drugs · 2020 · 26 citations

, , +8

A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation

Jennifer K. Litton, Marion E. Scoggins, David L. Ramírez et al. · Annals of Oncology · 2016 · 18 citations · Full text

, , +9

A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer

Clinton Yam, Elizabeth A. Mittendorf, Haven R. Garber et al. · Breast Cancer Research and Treatment · 2023 · 15 citations · Full text

, , +8

Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer

Akshara Singareeka Raghavendra, Nicole M. Kettner, Danielle Kwiatkowski et al. · npj Breast Cancer · 2025 · 10 citations · Full text

1–5 of 5